camurus®

Company presentation

April 2022

Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Long-acting medications addressing key healthcare challenges

Camurus' business overview

Rapidly growing commercial stage company

- Commercial infrastructure in EU and Australia
- Buvidal® Weekly and Monthly for opioid dependence available in 17 countries
- Strong sales performance and growth

Broad late-stage pipeline

- +10 innovative clinical programs in drug dependence, pain, and rare diseases
- Three Phase 3 programs
- Advancing early- and mid-stage candidates

Unique FluidCrystal® nanotechnologies

- New generation long-acting depot technology
- Validated in +25 clinical trials and by approved products

Partnerships

- R&D collaborations, licensing and royalty arrangements
- To use the full potential of our products and technology



LISTED ON NASDAQ STO; TICKER **CAMX** EMPLOYEES: **152** HQ: **Lund, Sweden** REGIONAL OFFICES: **Cambridge, Mannheim, Sydney**

camurus®

Leading FluidCrystal® extended-release technology

- ✓ Easy and convenient administration
- ✓ Rapid onset & long-acting release
- ✓ Applicable across substance classes
- ✓ Adopted to prefilled syringes and prefilled pens
- ✓ Manufacturing by standard processes
- ✓ Strong intellectual property



Sources: Tiberg F, et al. Chapter in Long Acting Injections and Implants, Advances in Delivery Science and Technology 2012; Tiberg F, et al. OnDrugDelivery 2010; Tiberg F, et al. Drug Del. Sci. Tech., 21 (1) 101-109 2011.

camurus®

FluidCrystal – Long-acting release of somatostatin analogues

Immediate release octreotide (Sandostatin®)



FluidCrystal injection depot



camurus.

Weekly and monthly buprenorphine depots

Population pharmacokinetic profiles for Buvidal® vs sublingual buprenorphine

Weekly Buvidal vs. Daily sublingual buprenorphine



Weekly vs. Monthly Buvidal



Population PK model analysis based on data from four clinical studies (N=236). Diagnostic testing demonstrated predictive buprenorphine concentrations and good agreement between observed and predicted data percentiles. Steady state data.

Sources: Abstract presented at the Annual conference of the Society for the Study of Addiction- November 2018; Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F. Adv Ther. 2017;34(2):560–575.

Opioid dependence – escalating global health crisis

Largest society burden of all drugs[1]

- 62 million opioid users worldwide[1]
- Opioid crisis worsened during COVID-19 pandemic
- US opioid overdose deaths has mounted during the pandemic and now exceed > 70,000 per year[2]

High need for better access to care and new treatment alternatives

Significant limitation with current daily medications

- Diversion, misuse, risk of overdose, poor retention, burdens and stigma of daily buprenorphine and methadone medications

[1] *United Nations: World drug report 2021*; [2] *www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm*

Escalating overdose deaths during COVID-19



camurus.

Buvidal – game changing opioid dependence treatment, ODT

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over[1]

Buvidal provides significant benefits to patients and society

– Rapid and effective suppression of withdrawal and cravings[1,2,3]
– Opioid blockade from the first dose[2]
– Superior treatment outcome and patient satisfaction[3-5]
– Reduced treatment burden and improved quality of life[5,6]
– Decreased risk of diversion, misuse and pediatric exposure[7,8]
– Reduced treatment costs in the criminal justice system[9]

[1] SmPC Buvidal May 2021; [2] Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; [3] Walsh et al, JAMA Psychiatry 2017;74(9):894-902; [4] Frost , M., et al. Addiction. 2019;114(8):1416-1426. doi: 10.1111/add.14636; [5] Lintzeris, N., et al. JAMA Network Open. 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041, [6] Barnett et al Drug and Alcohol Dependence 2021; https://doi.org/10.1016/j.drugalcdep.2021.108959 ; [7] EPAR for Buvidal; [8] Dunlop, A. J., et al. Addiction. 2021. https://doi.org/10.1111/add.15627; [9] Dunlop, A. Oral presentation at CPDD June 2020.

Growing patient numbers and market expansion

High patient shares and growth in established markets

- Over 60% Buvidal patient share in Finland, and ~10-20% shares in Scandinavia, Australia, Wales and Scotland 2-3 years from launch
- Total market growing, incl. in Australia and Finland
- Estimated ~25,000 patients in treatment

Market expansion continues

- Regulatory approval in Israel
- Pricing and reimbursement approval in Belgium
- New additional funding allocated for opioid dependence treatment and Buvidal in England, Scotland, Wales, France and Denmark

Positive outlook for continued growth

- Continue establishing leadership in opioid dependence treatment in Europe and Australia
- New launches in the EU and MENA
- On track to achieve goal of more than 100,000 patients in treatment with Buvidal in 2026

Quarterly product sales



Positive momentum for Buvidal in the UK

Increasing media attention

- Benefits of Buvidal recognized by wider society[1-3]
- Powerful patient stories in national and regional media[4,5]

BBC report 6 Dec 2021[5]:

New funding initiatives

- Scottish Government initiative £250m investment to tackle drug death crisis[1]
- England commits additional £780m over three years to improving drug addiction treatment[3]

UK 10-year drug plan published 6 Dec 2021[5]:



[1] www.gov.scot/publications/update-drugs-policy/; [2] https://gov.wales/more-must-be-done-tackle-substance-misuse-despite-fall-drug-deaths-vows-mental-health-minister; [3] https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1038722/From_harm_to_hope_PDF_FINAL.pdf; [4] Including www.bbc.com/news/uk-scotland-54433312, www.itv.com/news/granada/2021-05-19/the-game-changer-meds-helping-tackle-opioid-addiction; [5] https://www.bbc.com/news/uk-england-birmingham-59521413;

Broad and diversified mid- to late-stage pipeline



[1]Licensed to Braeburn in North America; [2]Licensed to Rhythm Pharmaceuticals worldwide

Buvidal (Brixadi) regulatory progress

New approvals and ongoing processes

- Market authorization in Israel and Lebanon, adding to approvals in EU, UK, Switzerland, Australia and New Zealand
- MAAs under review in three MENA countries with Fast Track in Saudi Arabia
- Further submissions in progress
- Early access programs in three countries

Brixadi™ in the US

- Braeburn issued with new Complete Response Letter (CRL) for the Brixadi NDA on 15 Dec 2021
- CRL result of quality-related deficiencies at Braeburn's US contract manufacturer
- Camurus waiting for information from Braeburn about NDA re-submission, including timelines



MAA – Marketing Authorization Application; MENA – Middle East and North Africa; FDA – US Food and Drug Administration; CRL – Complete Response Letter; NDA – New Drug Application;

Buvidal for treatment of chronic pain

Buvidal indication expansion

- Regulatory submission (type 2-variation) accepted by EMA for extension of Buvidal indication to include chronic pain
- CHMP opinion expected in H2 2022
- Submission to TGA in Australia planned for Q1 2022

High unmet medical need

- High unmet medical need in chronic pain, especially among people with dependence of opioids
- If approved, Buvidal could be the first long-acting injection product approved for treatment of chronic pain

Significant market potential

- Initial estimate of the added market potential of the proposed chronic pain indication for Buvidal in EU and Australia is ≥150 million EUR[1]

[1] *Company estimate subject to final indication approved by EC and TGA*

camurus.

CAM2029 – octreotide subcutaneous depot in Phase 3 development

Under development for three rare diseases: acromegaly, neuroendocrine tumors and polycystic liver disease

Designed for enhanced efficacy and improved patient convenience

camurus.

Established medical therapy with somatostatin analogs, but with limitations

Long-acting somatostatin analogues (SSAs) first-line medical treatment of acromegaly and neuroendocrine tumors[1]

— Recognized as safe and effective

— US$ 2.8 billion annual sales[2] of leading brands Sandostatin® LAR® and Somatuline® Autogel®

Clinical studies indicate effectiveness in treating polycystic liver disease[3-5]

— No approved pharmacological treatment available in the US and EU

However, current SSA treatments have limitations

— Suboptimal plasma exposure

— Limited biochemical control rates ~50%

— Disease progression and continued symptoms reducing patients' quality of life[6-9]

— Complex handling & administration impacting patient's treatment experience and autonomy[10]

Source: [1]Pavel M et al, Cancer Chemotherapy and Pharmacology 2019; 83:375–385; [2]Gevers T. J. G., et al. Liver Int. 2015 May;35(5):1607-14.. doi: 10.1111/liv.12726; [3] GlobalData 2022; [4]Pisani A., et al. Clin Gastroenterol Hepatol. 2016 Jul;14(7):1022-1030. doi: 10.1016/j.cgh.2015; [5] van Aerts R., et al., Gastroenterology. 2019 Aug;157(2):481-491. doi: 10.1053/j.gastro.2019.04.018: [6]Tsoli M, et al. Ther Adv Endocrinol Metab. 2018;10:2042018818804698; [7]Chau, Eur J Cancer Care (Engl.) 2013; [8]Ronde EM, Eur J Cancer Care (Engl.) 2021; [9]Pavel M, Ann Oncol 2020; [10]Darden C, J Patient Rep Outcomes 2021

CAM2029 – targeting key unmet medical needs in acromegaly, NET and PLD

Convenient dosing and patient self-administration

- Ready to use, with no need for mixing, reconstitution, or temperature conditioning
- Easy subcutaneous administration with pre-filled syringe (automatic safety device) or pre-filled pen (thin needle “non-visible" needle for pre-filled pen

Octreotide subcutaneous depot (CAM2029) product presentations

Enhanced octreotide exposure with potential for improved efficacy

- Rapid onset and long-acting octreotide release
- Approximately 500% higher bioavailability vs octreotide LAR[1, 2]
- Indicated well-maintained or improved disease and symptom control in acromegaly and NET[2]
- Potential first pharmacological treatment approved for PLD
- Safety profile comparable to well-established long-acting somatostatin analogues

NET: neuroendocrine tumors; PLD: polycystic liver disease.
Source: [1]Tiberg F, et al. Br J Clin Pharmacol. 2015 ;80:460-72. [2]Pavel M, et al. Cancer Chemother Pharmacol. 2019; 83:375–85.

camurus.

CAM2029 clinical study program overview

Four completed clinical trials characterizing PK, PD and safety in healthy subjects and patients (N=249)



ACRO Phase 3 RCT	ACRO Phase 3 OLE	GEP-NET Phase 3 RCT	PLD Phase 2/3 RCT	Prefilled pen PK
Randomized, double-blind, placebo-controlled trial in SSA responders	Open label, long-term safety trial in partial and full SSA responders	Active controlled Phase 3 trial in patients with metastatic/unresectable GEP-NET	Randomized, double-blind, placebo-controlled Phase 2/3 study in patients with polycystic liver disease	PK bridging study prefilled syringe and prefilled pen devices

Timelines are indicative. PK – pharmacokinetic; PD – pharmacodynamic; PC – Placebo control; LTSE – Long-term safety extension; ACRO – acromegaly, GEP-NET – gastroenteropancreatic neuroendocrine tumors; PLD – polycystic liver disease

Two ongoing pivotal Phase 3 studies of CAM2029 in acromegaly

Efficacy trial

- Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to assess efficacy and safety of CAM2029
- 78 patients, full SSA responders
- Regulatory requirements for efficacy data met
- **Primary endpoint:** Proportion of patients with mean IGF-1 levels ≤ 1x upper limit of normal (ULN) at w22 and w24
- Study ongoing and recruiting

Long-term safety trial

- Phase 3, open-label, single arm, multi-center trial to assess the long-term safety and efficacy of CAM2029
- ≥ 100 patients exposed to CAM2029 for 12 months
  - Roll-over patients from HS-18-633 and
  - 'New patients' (partial SSA responders, irradiated patients, and full SSA responders)
- **Primary endpoint:** Safety profile (adverse events)
- Study ongoing and recruiting



SORENTO™

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine TumOrs

CAM2029 Phase 3 trial assessing superiority in progression free survival in GEP-NET

- ✓ Phase 3, randomized, open-label, active-controlled, multi-center trial to assess efficacy and safety of CAM2029 versus standard of care in patients with GEP-NET
  - – Approximately 300 patients with metastatic/unresectable GEP-NET, randomized 1:1
  - – **Primary endpoint:** Increased progression free survival with CAM2029 vs. lanreotide ATG or octreotide LAR in patients with advanced, well differentiated GEP-NET
  - – Randomization and treatment

Patient population

– Adult patients with histologically confirmed advanced (unresectable and/or metastatic) and well-differentiated NET of GEP origin



SSA, somatostatin analogue; GEP, gastroenteropancreatic; LAR, long-acting release; NET, neuroendocrine tumours; RCT, randomized controlled trial

Significant market potential for CAM2029

Acromegaly

– Chronic disorder caused by excess growth hormone (GH) secretion from benign pituitary tumor

Estimated 51,000 patients with 18,000 on SSA[1,2]

Neuroendocrine tumors (NET)

– Chronic, life-limiting disease which in some patients is associated with severe symptoms (carcinoid syndrome)

Estimated 390,000 patients with 51,000 on SSA[2]

Polycystic liver disease (PLD)

– Chronic disorder characterized by progressive growth of liver cysts, which can cause severe symptoms

Estimated 37,000 target patients with symptomatic PLD[3]

CAM2029 peak sales estimate in the EU and the US:[3]

ACRO: US$ **120 – 180** million



NET: US$ **720 – 1020** million



PLD: US$ **270 – 420** million



[1] https://rarediseases.org/rare-diseases/acromegaly/; [2] Est. in US and EU4+UK. Globe Life Sciences report 2019; data on file, [3] Est. in US and EU4+UK. Globe Life Sciences report 2020; data on file ; [4] Globe Life Sciences report 2020 and Company estimates
SSA – somatostatin analog

First dosing in Phase 3 program for weekly setmelanotide

Weekly setmelanotide for genetic obesity disorders

- ✓ Weekly formulation of setmelanotide based on Camurus' FluidCrystal technology
- ✓ Daily formulation of setmelanotide, IMCIVREE™ , approved by the FDA in Nov 2020[1] and EC in Jul 2021[1,2]

Phase 3 "switch study"

- – Randomized, double-blind (13+13 w) trial in patients with eg. Bardet-Biedl Syndrome (BBS) switched from daily therapy[3]
- – 30 patients randomized 1:1
- – Primary endpoint: Proportion of patients with no weight gain
- ✓ **Dosing initiated Jan 2022[3]**

Phase 3 "de novo study"

- – Additional study in de novo patients planned by Rhythm

[1] https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-fda-approval-imcivreetm; [2] https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-european-commission; [3] https://news.cision.com/camurus-ab/r/camurus-announces-dosing-initiated-in-phase-3-trial-of-weekly-setmelanotide-in-patients-with-genetic,c3485863



Weekly formulation of setmelanotide designed to improve compliance and adherence

Strategies for continued value creation

Commercialization

- Establish leadership in opioid dependence treatment in Europe, and Australia
- **Expand into new markets and geographies**
- Market preparations for launches in chronic pain and acromegaly

Innovation and pipeline

- Advance our **late-stage pipeline programs in CNS and rare diseases**
- Invest in patient centric innovation and new differentiated product candidates
- Progress our leading FluidCrystal technology platform and partnerships

Corporate development

- Expand our commercial footprint
- Attain complementary products
- Deliver key catalysts for growth
- Reach **sustained profitability** through own sales, partnerships and business development

Rhythm to start Phase 3 trials evaluating weekly formulation of setmelanotide

Weekly setmelanotide for genetic obesity disorders

- ✓ Daily formulation of setmelanotide, IMCIVREE™, approved by the FDA in Nov 2020[1] and EC in Jul 2021[1,2]

Phase 3 trials in preparation after positive Phase 1-2a results

- ✓ Pharmacokinetic profiles supporting weekly dosing
- ✓ Similar weight loss to approved daily formulation
- ✓ Comparable safety profile

Phase 3 "switch study"

- Randomized, double-blind (13+13 w) trial in patients with eg. Bardet-Biedl Syndrome (BBS) switched from daily therapy[3]
- 30 patients randomized 1:1
- **Primary endpoint:** Proportion of patients with no weight gain

Phase 3 "de novo study"

- Randomized, double-blind placebo-controlled (18+14 w) trial in de novo patients with BBS[3]
- 40 naive patients randomized 1:1
- **Primary endpoint:** Mean change in weight compared to placebo



Weekly formulation of setmelanotide designed to improve compliance and adherence

[1] https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-fda-approval-imcivreetm; [2] https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-european-commission; [3] https://ir.rhythmtx.com/static-files/76ff1486-4b0b-4142-86c1-b1f7ff5b0de0

Strategies for continued value creation

Commercialization

- Establish leadership in opioid dependence treatment in Europe, and Australia
- **Expand into new markets and geographies**
- Market preparations for launches in chronic pain and acromegaly

Innovation and pipeline

- Advance our **late-stage pipeline programs in CNS and rare diseases**
- Invest in patient centric innovation and new differentiated product candidates
- Progress our leading FluidCrystal technology platform and partnerships

Corporate development

- Expand our commercial footprint
- Attain complementary products
- Deliver key catalysts for growth
- Reach **sustained profitability** through own sales, partnerships and business development

Appendix

Camurus AB | Ideon Science Park, SE-223 70 Lund, Sweden
P +46 46 286 57 30 | info@camurus.com | camurus.com

camurus.

Significant peak market potential for Buvidal/Brixadi

EU and Australia

– 1,400,000 high risk opioid users and 750,000 in ODT[1]
– Estimated LAI peak sales

€300-400 million[2]

based on 15-20% ODT patient share

United States

– More than 10 million misuse opioids[3]
– About 1.4 million in OUD treatment, and one million receiving buprenorphine[3,4]
– Estimated LAI peak sales

$1.5 – 2 billion[5]

based on 10-15% OUD patient share and current price level



MENA

– More than 300k people with opioid dependence[6]
– Estimated LAI peak sales

€25-75 million[7]

LAI, long-acting injectables; ODT, opioid dependence treatment; OUD, opioid use disorder

[1]European Drug Report 2020 and https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/nopsad-2018/contents/introduction%C2%A0; [2]Camurus estimate; [3]SAMHSA, Results from the 2019 National Survey on Drug Use and Health, Sep. 2020, Tables ; [4]Symphony Health, 2018; [5]Indivior Second Quarter and First Half 2021 Financial Results Presentation and Camurus estimates; [6]World Drug Report and NewBridge estimate; [7]Camurus estimate

camurus

Continued high activity to disseminate scientific evidence base for Buvidal

Planned scientific conferences in 2022

	Q1	Q2	Q3	Q4
Global	**ASAM** 31-Mar- 3 Apr Hollywood, FL, USA	**CPDD** 11-15 Jun Minneapolis, USA		**ISAM** 4-7 Oct Valetta, Malta
European	**Nordic Op Sym.** 3-4 Feb Uppsala, Sweden	**IOTOD** 11-12 May Virtual **EUROPAD** 20-22 May Pisa, Italy	**ALBATROS** 8-10 Jun Paris, France	**Lisbon Addict.** 23-25 Nov Lisbon, Portugal
National (selected)	**Cong. L'Encepha.** 19-21 Jan Paris, France **Dt. Schmerz+ Palliativ-Tag** 23-26 Mar Frankfurt, Germany **SMMGP RCGP** 25-26 Mar London, United Kingdom	**Subst.-Forum** 14-15 May Mondsee, Austria **CPNLF** 15-17 Jun Nice, France **IMIA21** TBD Virtual	**RCPysch Int.** 20-23 Jun TBD United Kingdom **Kon. Suchtmed.** 30 Jun-2 Jul Munich, Germany **Adictologia** TBD Portugal	**DGS-Kon.** 26-30 Sep Bielefeld, Germany **SEPD** 23-24 Sep Gran Canaria, ES **Schmerzkon.** TBD Germany	**SESP (Prisons)** TBD TBD, Spain **Beroendemedicin** TBD Sweden **J Sociodrog** TBD Spain	**SSA Conf.** TBD United Kingdom **APSAD** TBD Australia **Feder SerD** TBD Italy	**SIPaD** TBD Italy **Gefängnis medizin** TBD Germany **Int. Suchtsymp** TBD Austria

Key publications in 2021[1-5]

[1]Lintzeris et al. JAMA Network Open. 2021;4(5):e219041. [2]Compton et al. JAMA Network Open. 2021;4(5):e219708.; [3]Dunlop et al. Addiction. Jun 29, 2021. [4]Barnett et al. Drug and Alcohol Dependence. Oct 1, 2021; [5]Soyka M., et al. Am J Drug Alcohol Abuse. 47: 599-604, 2021

Financials - third quarter and nine months 2021

MSEK	Jul – Sep 2021	Jul – Sep 2020	Δ	Jan – Sep 2021	Jan – Sep 2020	Δ	Jan – Dec 2020
Total revenues	154	100	54%	418	230	81%	336
whereof product sales	152	94	61%	413	219	89%	323
Operating expenses	139	113	23%	454	333	37%	508
Operating result	-6	-23	73%	-92	-124	25%	-205
Result for the period	-6	-20	70%	-76	-102	25%	-167
Result per share, before and after dilution, SEK	-0.11	-0.38	70%	-1.41	-1.95	28%	-3.18
Cash position	426	476	-10%	426	476	-10%	462

Shareholders

Shareholders as of 30 December 2021	Number of shares	% of capital	% of votes
Sandberg Development AB	21,875,692	39.9	39.9
Fjärde AP-fonden	3,330,676	6.1	6.1
Avanza Pension	2,723,086	5.0	5.0
Fredrik Tiberg, CEO	1,672,788	3.0	3.0
Didner & Gerge Fonder	1,518,133	2.8	2.8
Svenskt Näringsliv	1,150,000	2.1	2.1
Lancelot Avalon	1,025,000	1.9	1.9
Backahill Utveckling	826,491	1.5	1.5
CMU/SECFIN Pooled Account	732,271	1.3	1.3
State Street Bank and Trust	665,915	1.2	1.2
Cancerfonden	580,000	1.1	1.1
Afa Försäkring	545,660	1.0	1.0
Camurus Lipid Research Foundation	505,250	0.9	0.9
JP Morgan Chase Bank	500,584	0.9	0.9
Carl-Olof and Jenz Hamrins Stiftelse	425,000	0.8	0.8
Other shareholders	16,715,886	30.5	30.5
In total	**54,792,432**	**100.0**	**100.0**

Shareholder distribution



Experienced and committed management team

Fredrik Tiberg, PhD
President & CEO, Head R&D
In Company since: *2002*
Holdings*: 1,672,788 shares, 90,000 warrants & 60,000 employee options*

Education: M.Sc. in Chemical Engineering, PhD in Physical Chemistry, Lund University

Previous experience: Professor in Physical Chemistry at Lund University, Visiting Professor at Oxford University, Institute for Surface Chemistry (Section head).

Richard Jameson
Chief Commercial Officer
In Company since: *2016*
Holdings*: 25,193 shares, 58,000 warrants and 33,750 employee options*

Education: B.Sc. in Applied Biological Sciences from University West of England

Previous experience: General Manager, UK & Nordics for Reckitt Benckiser (2010 – 2013) and Area Director Europe, Middle East and Africa for Indivior (2013 – 2016).

Fredrik Joabsson, PhD
Chief Business Dev. Officer
In Company since: *2001*
Holdings*: 49,170 shares , 15,000 subscription warrants & 22,500 employee options*

Education: M.Sc. in Chemistry, PhD in Physical Chemistry, Lund University

Previous experience: More than 20 years of experience in pharmaceutical R&D, business development and alliance management.

Annette Mattsson
VP Regulatory Affairs
In Company since: *2017*
Holdings*: 1,504 shares, 7,000 subscription warrants & 22,500 employee options*

Education: Bachelor of Pharmacy, Uppsala University and Business Economics, Lund University

Previous experience: More than 25 years of experience within regulatory affairs, including European RA Director/Global RA Lead at AstraZeneca and Global RA Lead at LEO Pharma.

Andrew McLean
VP Corporate Development & Senior Counsel
In Company since: *2021*
Holdings*: 22,500 employee options*

Education: Bachelor of Laws (LL.B (Hons)), Aberystwyth University and College of Law, Guildford (Law Finals)

Previous experience: General Counsel, Company Secretary & Chief Compliance Officer at Kyowa Kirin International, International Business Lawyer at Recordati SpA, Head of Legal Affairs at Shire Pharmaceuticals

Jon Garay Alonso
Chief Financial Officer
In Company since: *2022*
Holdings*: 1,450 shares & 33,750 employee options*

Education: Bachelor in Business Administration by Universidad Comercial de Deusto. Executive MBA by IESE Business School.

Previous experience: More than 20 years experience from Finance within pharmaceutical and MedTech companies, incl. Baxter, Gambro, Convatec, Bristol Myers Squibb.

Peter Hjelmström, MD, PhD
Chief Medical Officer
In Company since: *2016*
Holdings*: 22,500 employee options*

Education: MD, PhD and Associate Professor from Karolinska Institutet, Postdoctoral fellowship at Yale University

Previous experience: More than 15 years of experience from the pharmaceutical industry, including as Medical Director at Orexo and Head of Clinical Science at Sobi

Maria Lundqvist
Head of Global HR
In Company since: *2021*
Holdings*: 1,000 subscription warrants, 22,500 employee options*

Education: B.Sc: in Business and Economics, Uppsala University

Previous experience: More than 20 years of experience of leadership roles within Human Resources, including HR Director Nordics at Teva Pharmaceuticals and HR positions at Tetra Pak, Vestas and AstraZeneca.

Torsten Malmström, PhD
Chief Technical Officer
In Company since: *2013*
Holdings*: 46,858 shares & 22,500 employee options*

Education: M.Sc. in Chemistry, PhD in Inorganic Chemistry, Lund University

Previous experience: More than 20 years of experience from pharmaceutical R&D including Director Pharmaceutical Development at Zealande Pharma, Director of Development at Polypeptide, Team Manager at AstraZeneca.

Agneta Svedberg
VP Clinical & Regulatory Dev.
In Company since: *2015*
Holdings*: 17,987 shares, 25,000 subscription warrants & 22,500 employee options*

Education: M.Sc. In Radiophysics and B.Sc. In Medicine from Lund University, Executive MBA from Executive Foundation Lund

Previous experience: More than 25 years of experience in drug development, incl. as COO at Zealand Pharma, CEO of Cantargia, Senior VP Clinical Development at Genmab.